Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 662 entries
Sorted by: Best Match Show Resources per page
Risk Reduction Strategies in Breast Cancer Prevention.

European journal of breast health

Costa M, Saldanha P.
PMID: 28894848
Eur J Breast Health. 2017 Jul 01;13(3):103-112. doi: 10.5152/ejbh.2017.3583. eCollection 2017 Jul.

Evaluating the risk of breast cancer makes it possible to identify women with a high risk of developing breast cancer in the future. Adopting a healthier lifestyle, involving diet and exercise, is one way of reducing this risk-but there...

Cite
Costa M, Saldanha P. Risk Reduction Strategies in Breast Cancer Prevention. Eur J Breast Health. 2017;13(3):103-112doi: 10.5152/ejbh.2017.3583.
Costa, M., & Saldanha, P. (2017). Risk Reduction Strategies in Breast Cancer Prevention. European journal of breast health, 13(3), 103-112. https://doi.org/10.5152/ejbh.2017.3583
Costa, Mauricio, and Saldanha, Paula. "Risk Reduction Strategies in Breast Cancer Prevention." European journal of breast health vol. 13,3 (2017): 103-112. doi: https://doi.org/10.5152/ejbh.2017.3583
Costa M, Saldanha P. Risk Reduction Strategies in Breast Cancer Prevention. Eur J Breast Health. 2017 Jul 01;13(3):103-112. doi: 10.5152/ejbh.2017.3583. eCollection 2017 Jul. PMID: 28894848; PMCID: PMC5544140.
Copy Download .nbib Format: NLM
Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT.

International journal of reproductive biomedicine

Ebrahimi M, Akbari-Asbagh F, Ghalandar-Attar M.
PMID: 28462402
Int J Reprod Biomed. 2017 Feb;15(2):101-108.

BACKGROUND: Gonadotropin-releasing hormone (GnRH) antagonist protocol has been proposed as a potentially proper option for the patients with limited ovarian reserve. Nevertheless, there is no significant difference in terms of clinical pregnancy between the GnRH antagonist and agonist cycles....

Cite
Ebrahimi M, Akbari-Asbagh F, Ghalandar-Attar M. Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT. Int J Reprod Biomed. 2017;15(2):101-108
Ebrahimi, M., Akbari-Asbagh, F., & Ghalandar-Attar, M. (2017). Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT. International journal of reproductive biomedicine, 15(2), 101-108.
Ebrahimi, Mahbod, et al. "Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT." International journal of reproductive biomedicine vol. 15,2 (2017): 101-108.
Ebrahimi M, Akbari-Asbagh F, Ghalandar-Attar M. Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT. Int J Reprod Biomed. 2017 Feb;15(2):101-108. PMID: 28462402; PMCID: PMC5405223.
Copy Download .nbib Format: NLM
Adenomyosis: a systematic review of medical treatment.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Pontis A, D'Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S.
PMID: 27379972
Gynecol Endocrinol. 2016 Sep;32(9):696-700. doi: 10.1080/09513590.2016.1197200. Epub 2016 Jul 05.

Adenomyosis is a heterogeneous gynaecologic condition with a range of clinical presentations, the most common being heavy menstrual bleeding and dysmenorrhoea; however, patients can also be asymptomatic. Several studies support the theory that adenomyosis results from invasion of the...

Cite
Pontis A, D'Alterio MN, Pirarba S, et al. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016;32(9):696-700doi: 10.1080/09513590.2016.1197200.
Pontis, A., D'Alterio, M. N., Pirarba, S., de Angelis, C., Tinelli, R., & Angioni, S. (2016). Adenomyosis: a systematic review of medical treatment. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 32(9), 696-700. https://doi.org/10.1080/09513590.2016.1197200
Pontis, A, et al. "Adenomyosis: a systematic review of medical treatment." Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology vol. 32,9 (2016): 696-700. doi: https://doi.org/10.1080/09513590.2016.1197200
Pontis A, D'Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016 Sep;32(9):696-700. doi: 10.1080/09513590.2016.1197200. Epub 2016 Jul 05. PMID: 27379972.
Copy Download .nbib Format: NLM
Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory.

Breast cancer : basic and clinical research

Karmakar M, Pinto SL, Jordan TR, Mohamed I, Holiday-Goodman M.
PMID: 28469437
Breast Cancer (Auckl). 2017 Mar 02;11:1178223417694520. doi: 10.1177/1178223417694520. eCollection 2017.

The purpose of this observational study was to determine if the Protection Motivation Theory could predict and explain adherence to aromatase inhibitor (AI) therapy among breast cancer survivors. Purposive sampling was used to identify 288 survivors who had been...

Cite
Karmakar M, Pinto SL, Jordan TR, et al. Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory. Breast Cancer (Auckl). 2017;11:1178223417694520doi: 10.1177/1178223417694520.
Karmakar, M., Pinto, S. L., Jordan, T. R., Mohamed, I., & Holiday-Goodman, M. (2017). Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory. Breast cancer : basic and clinical research, 111178223417694520. https://doi.org/10.1177/1178223417694520
Karmakar, Monita, et al. "Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory." Breast cancer : basic and clinical research vol. 11 (2017): 1178223417694520. doi: https://doi.org/10.1177/1178223417694520
Karmakar M, Pinto SL, Jordan TR, Mohamed I, Holiday-Goodman M. Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory. Breast Cancer (Auckl). 2017 Mar 02;11:1178223417694520. doi: 10.1177/1178223417694520. eCollection 2017. PMID: 28469437; PMCID: PMC5391055.
Copy Download .nbib Format: NLM
Are patients with newly diagnosed breast cancer getting appropriate DEXA scans? A District General Hospital experience.

BMJ quality improvement reports

Dong H, Dayananda P, Preece SA, Carmichael A.
PMID: 26734446
BMJ Qual Improv Rep. 2015 Nov 17;4(1). doi: 10.1136/bmjquality.u209414.w3856. eCollection 2015.

Breast cancer patients are often at high risk of fragility fractures partly due to adjuvant endocrine therapy such as aromatase inhibitors and chemotherapy. Baseline dual energy X-ray absorptiometry (DEXA) scanning is recommended as a standard of care in identifying...

Cite
Dong H, Dayananda P, Preece SA, et al. Are patients with newly diagnosed breast cancer getting appropriate DEXA scans? A District General Hospital experience. BMJ Qual Improv Rep. 2015;4(1)doi: 10.1136/bmjquality.u209414.w3856.
Dong, H., Dayananda, P., Preece, S. A., & Carmichael, A. (2015). Are patients with newly diagnosed breast cancer getting appropriate DEXA scans? A District General Hospital experience. BMJ quality improvement reports, 4(1), . https://doi.org/10.1136/bmjquality.u209414.w3856
Dong, Huan, et al. "Are patients with newly diagnosed breast cancer getting appropriate DEXA scans? A District General Hospital experience." BMJ quality improvement reports vol. 4,1 (2015). doi: https://doi.org/10.1136/bmjquality.u209414.w3856
Dong H, Dayananda P, Preece SA, Carmichael A. Are patients with newly diagnosed breast cancer getting appropriate DEXA scans? A District General Hospital experience. BMJ Qual Improv Rep. 2015 Nov 17;4(1). doi: 10.1136/bmjquality.u209414.w3856. eCollection 2015. PMID: 26734446; PMCID: PMC4693105.
Copy Download .nbib Format: NLM
Extending aromatase inhibitor sensitivity in hormone resistant breast cancer.

Hormone molecular biology and clinical investigation

Brodie AM, Chumsri S, Sukumar S, Sabnis GJ.
PMID: 25961245
Horm Mol Biol Clin Investig. 2011 Mar 01;5(2):97-103. doi: 10.1515/HMBCI.2011.010.

Aromatase inhibitors (AIs) are first-line treatment for ER+ breast cancer. However, despite responses initially, some patients can eventually acquire resistance. Moreover, 25% of all breast cancer patients do not express the estrogen receptor (ERĪ±) and are innately resistance. In...

Cite
Brodie AM, Chumsri S, Sukumar S, et al. Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. Horm Mol Biol Clin Investig. 2011;5(2):97-103doi: 10.1515/HMBCI.2011.010.
Brodie, A. M., Chumsri, S., Sukumar, S., & Sabnis, G. J. (2011). Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. Hormone molecular biology and clinical investigation, 5(2), 97-103. https://doi.org/10.1515/HMBCI.2011.010
Brodie, Angela M H, et al. "Extending aromatase inhibitor sensitivity in hormone resistant breast cancer." Hormone molecular biology and clinical investigation vol. 5,2 (2011): 97-103. doi: https://doi.org/10.1515/HMBCI.2011.010
Brodie AM, Chumsri S, Sukumar S, Sabnis GJ. Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. Horm Mol Biol Clin Investig. 2011 Mar 01;5(2):97-103. doi: 10.1515/HMBCI.2011.010. PMID: 25961245.
Copy Download .nbib Format: NLM
Medical prevention of breast cancer.

Breast care (Basel, Switzerland)

Stubert J, Dieterich M, Gerber B.
PMID: 25759621
Breast Care (Basel). 2014 Dec;9(6):391-6. doi: 10.1159/000369573.

Breast cancer is the most common cancer of women in Western Europe and North America. Effective strategies of medical prevention could reduce the burden of breast cancer mortality. The best evidence for a risk reduction exists for hormonal agents...

Cite
Stubert J, Dieterich M, Gerber B. Medical prevention of breast cancer. Breast Care (Basel). 2014;9(6):391-6doi: 10.1159/000369573.
Stubert, J., Dieterich, M., & Gerber, B. (2014). Medical prevention of breast cancer. Breast care (Basel, Switzerland), 9(6), 391-6. https://doi.org/10.1159/000369573
Stubert, Johannes, et al. "Medical prevention of breast cancer." Breast care (Basel, Switzerland) vol. 9,6 (2014): 391-6. doi: https://doi.org/10.1159/000369573
Stubert J, Dieterich M, Gerber B. Medical prevention of breast cancer. Breast Care (Basel). 2014 Dec;9(6):391-6. doi: 10.1159/000369573. PMID: 25759621; PMCID: PMC4317676.
Copy Download .nbib Format: NLM
Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor.

Oncology letters

Ohara M, Akimoto E, Noma M, Matsuura K, Doi M, Kagawa N, Itamoto T.
PMID: 26722327
Oncol Lett. 2015 Nov;10(5):3286-3292. doi: 10.3892/ol.2015.3655. Epub 2015 Aug 28.

Aromatase inhibitors have played a central role in endocrine therapy for the treatment of estrogen receptor (ER)-positive breast cancer in postmenopausal patients. However, prognostic factors for recurrence following such treatment have not been identified. The current study aimed to...

Cite
Ohara M, Akimoto E, Noma M, et al. Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor. Oncol Lett. 2015;10(5):3286-3292doi: 10.3892/ol.2015.3655.
Ohara, M., Akimoto, E., Noma, M., Matsuura, K., Doi, M., Kagawa, N., & Itamoto, T. (2015). Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor. Oncology letters, 10(5), 3286-3292. https://doi.org/10.3892/ol.2015.3655
Ohara, Masahiro, et al. "Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor." Oncology letters vol. 10,5 (2015): 3286-3292. doi: https://doi.org/10.3892/ol.2015.3655
Ohara M, Akimoto E, Noma M, Matsuura K, Doi M, Kagawa N, Itamoto T. Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor. Oncol Lett. 2015 Nov;10(5):3286-3292. doi: 10.3892/ol.2015.3655. Epub 2015 Aug 28. PMID: 26722327; PMCID: PMC4665350.
Copy Download .nbib Format: NLM
Molecular Action and Clinical Relevance of Aromatase Inhibitors.

The oncologist

Murphy MJ.
PMID: 10388095
Oncologist. 1998;3(2):129-130.

BREAST CANCER: HIGH PREVALENCE AND RISING INCIDENCE: Breast cancer is the most common form of cancer among women in Europe, North and South America and Australasia; approximately 1 in 10 women in Western countries will develop breast cancer during...

Cite
Murphy MJ. Molecular Action and Clinical Relevance of Aromatase Inhibitors. Oncologist. 1998;3(2):129-130
Murphy, M. J. (1998). Molecular Action and Clinical Relevance of Aromatase Inhibitors. The oncologist, 3(2), 129-130.
Murphy. "Molecular Action and Clinical Relevance of Aromatase Inhibitors." The oncologist vol. 3,2 (1998): 129-130.
Murphy MJ. Molecular Action and Clinical Relevance of Aromatase Inhibitors. Oncologist. 1998;3(2):129-130. PMID: 10388095.
Copy Download .nbib Format: NLM
New Hormonal Therapies for Breast Cancer.

Cancer control : journal of the Moffitt Cancer Center

Minton SE.
PMID: 10758554
Cancer Control. 1999 May;6(3):247-255. doi: 10.1177/107327489900600303.

BACKGROUND: There has been an explosion in the development of hormonal therapies for the treatment of breast cancer. Several new agents have been approved for the treatment of breast cancer in the metastatic setting, and trials are ongoing in...

Cite
Minton SE. New Hormonal Therapies for Breast Cancer. Cancer Control. 1999;6(3):247-255doi: 10.1177/107327489900600303.
Minton, S. E. (1999). New Hormonal Therapies for Breast Cancer. Cancer control : journal of the Moffitt Cancer Center, 6(3), 247-255. https://doi.org/10.1177/107327489900600303
Minton. "New Hormonal Therapies for Breast Cancer." Cancer control : journal of the Moffitt Cancer Center vol. 6,3 (1999): 247-255. doi: https://doi.org/10.1177/107327489900600303
Minton SE. New Hormonal Therapies for Breast Cancer. Cancer Control. 1999 May;6(3):247-255. doi: 10.1177/107327489900600303. PMID: 10758554.
Copy Download .nbib Format: NLM
The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial.

Current oncology (Toronto, Ont.)

Richardson H, Johnston D, Pater J, Goss P.
PMID: 17593981
Curr Oncol. 2007 Jun;14(3):89-96. doi: 10.3747/co.2007.117.

Several large phase III trials have demonstrated that tamoxifen-and more recently, raloxifene-can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events....

Cite
Richardson H, Johnston D, Pater J, et al. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007;14(3):89-96doi: 10.3747/co.2007.117.
Richardson, H., Johnston, D., Pater, J., & Goss, P. (2007). The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Current oncology (Toronto, Ont.), 14(3), 89-96. https://doi.org/10.3747/co.2007.117
Richardson, H, et al. "The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial." Current oncology (Toronto, Ont.) vol. 14,3 (2007): 89-96. doi: https://doi.org/10.3747/co.2007.117
Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007 Jun;14(3):89-96. doi: 10.3747/co.2007.117. PMID: 17593981; PMCID: PMC1899358.
Copy Download .nbib Format: NLM
Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?.

Nature clinical practice. Oncology

Schiff R, Lee AV.
PMID: 16520802
Nat Clin Pract Oncol. 2006 Mar;3(3):134-5. doi: 10.1038/ncponc0444.

No abstract available.

Cite
Schiff R, Lee AV. Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?. Nat Clin Pract Oncol. 2006;3(3):134-5doi: 10.1038/ncponc0444.
Schiff, R., & Lee, A. V. (2006). Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?. Nature clinical practice. Oncology, 3(3), 134-5. https://doi.org/10.1038/ncponc0444
Schiff, Rachel, and Lee, Adrian V. "Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?." Nature clinical practice. Oncology vol. 3,3 (2006): 134-5. doi: https://doi.org/10.1038/ncponc0444
Schiff R, Lee AV. Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?. Nat Clin Pract Oncol. 2006 Mar;3(3):134-5. doi: 10.1038/ncponc0444. PMID: 16520802.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 662 entries